Last Price
4.00
Today's Change
+0.01 (0.25%)
Day's Change
3.97 - 4.03
Trading Volume
233,531
Market Cap
98 Million
Shares Outstanding
24 Million
Avg Volume
83,435
Avg Price (50 Days)
3.28
Avg Price (200 Days)
2.43
PE Ratio
30.77
EPS
0.13
Earnings Announcement
05-Feb-2025
Previous Close
3.99
Open
3.99
Day's Range
3.97 - 4.03
Year Range
1.47 - 5.56
Trading Volume
233,531
1 Day Change
0.25%
5 Day Change
-12.85%
1 Month Change
21.21%
3 Month Change
55.04%
6 Month Change
76.99%
Ytd Change
15.94%
1 Year Change
60.64%
3 Year Change
38.89%
5 Year Change
14.61%
10 Year Change
-4.76%
Max Change
-46.67%
No result.
Sector: Healthcare - Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Description:
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.